Pharmaceuticals

Sterne Kessler works with branded pharmaceutical companies as well as biosimilars and generic drug companies to protect, enforce, and defend their intellectual property.

Sterne Kessler's pharmaceuticals practice integrates deep technical knowledge with legal acumen to develop robust patent portfolios, address patent validity challenges at the PTAB, and handle high-profile patent litigation, including Abbreviated New Drug Application (ANDA) and Biologics Price Competition and Innovation Act (BPCIA) matters. We work effectively with our clients to align IP with corporate strategy, and understand the advancements in life sciences that are shaping the IP landscape. Prescription & OTC Drugs Our pharmaceuticals team helps small molecule drug companies across the full range of IP—from patent prosecution and strategy, to opinions and litigation. Infectious Disease Treatments Sterne Kessler protects and defends drug and vaccine innovations developed to fight against infectious diseases. Generic Drug Development We work with generic drug developers to navigate the interface between patent law and the FDA approval process, as well as patent litigation and Abbreviated New Drug Application (ANDA) matters.

Related News & Insights

Bylined Articles

March 11, 2014

IPR: A 2nd Bite At The Apple For Hatch-Waxman Litigants

Law360

MarkIt to Market®

February 26, 2014

MarkIt to Market – February 2014

Publication

February 26, 2014

Service Marks Must be Used in Rendering of Services, Not Just Advertising

Sterne, Kessler, Goldstein & Fox